Back HIV/AIDS HIV/AIDS Topics HIV Treatment

AIDS 2014: Switching ART with Suppressed Viral Load Linked to Treatment Failure

People who switch away from their initial antiretroviral therapy (ART) regimen when their viral load is undetectable may have a higher likelihood of subsequent virological failure, researchers reported at the 20thInternational AIDS Conference last week in Melbourne. However, the association varied across groups and the researchers suggested their findings may reflect issues such as adherence difficulties or treatment changes due to pregnancy.

alt

Read more:

Of Guidelines Targets, and Resources -- Documents that Defined AIDS 2014

If there was a phrase that defined the 20th International AIDS Conference last week in Melbourne -- one that surfaced in every few presentations and kept turning up in documents -- it was "key affected populations." New World Health Organization (WHO) guidelines released in conjunction with AIDS 2014 recommend pre-exposure prophylaxis (PrEP) as an option for gay men at risk for HIV infection and naloxone to prevent overdoses among people who inject drugs (PWID).

alt

Read more:

Coverage of the 2014 International AIDS Conference

HIVandHepatitis.com coverage of the 20th International AIDS Conference (AIDS 2014), July 20-25, in Melbourne, Australia.

Conference highlights include biomedical HIV prevention (PrEP and treatment-as-prevention), HIV cure research, interferon-free therapy for hepatitis C and HIV/HCV coinfection, access to treatment, and fighting stigma and criminalization of key affected populations.

Full listing by topic

7/25/14

alt

AIDS 2014: Dolutegravir Demonstrates Good Efficacy Despite Resistance

Antiretroviral regimens containing the recently approved HIV integrase inhibitor dolutegravir (Tivicay) demonstrated high rates of viral suppression even in treatment-experienced people who were resistant to NRTIs. Among people starting treatment for the first time, no resistance was detected through 96 weeks, according to study findings presented at the 20th International AIDS Conference last week in Melbourne.

alt

Read more:

AIDS 2014: Researchers Discuss Progress Towards an HIV Cure [VIDEO]

Progress along the multi-pronged path towards a cure for HIV was one of the themes at the 20th International AIDS Conference (AIDS 2014), taking place this week in Melbourne. Researchers provided updates on the "Mississippi Baby," a novel assay for detecting low levels of hidden virus in the body, and using the anti-cancer drug romidepsin to reactivate latent virus.

alt

Read more:

AIDS 2014 Conference Highlight from Sharon Lewin [VIDEO]

As the 20th International AIDS Conference drew to a close in Melbourne, AIDS 2014 co-chair Sharon Lewin offered an overview of some highlights of the meeting at a Friday press briefing.

alt

Read more:

AIDS 2014: Romidepsin Activates Latent HIV, But Does Not Decrease Viral Reservoir

The HDAC inhibitor romidepsin was able to awaken latent HIV in resting T-cells, causing it to start producing new virus, but this was not associated with a decrease in the size of the viral reservoir in T-cells, researchers reported at the 20th International AIDS Conference this week in Melbourne. This finding suggests that kicking HIV out of hiding will not be adequate for a functional cure without strengthening immune response against the virus.

alt

Read more: